Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer
Arrizabalaga L, García-Torralba E, Galluzzi L, Buqué A. Targeting CDK2 to circumvent treatment resistance in HR+ breast cancer. Trends In Molecular Medicine 2024, 31: 495-497. PMID: 39732571, DOI: 10.1016/j.molmed.2024.12.009.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply